Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aripiprazole (Otsuka Pharmaceutical Co).

Vural Ozdemir1, Jeanne Fourie, Fatih Ozdener

  • 1Department of Pharmacology, University of Toronto, Ontario, Canada. vural.ozdemir@utoronto.ca

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary

Aripiprazole, a novel antipsychotic, acts as a dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. It shows promise for treating psychoses like schizophrenia with a favorable safety profile and low risk of extrapyramidal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to Oral Nutritional Support and Its Effect on Nutritional Status in Pediatric Oncology Patients.

Nutrition and cancer·2025
Same author

From the Editor's Desk: A Farewell and Salute to <i>OMICS</i>.

Omics : a journal of integrative biology·2025
Same author

Queering and Decolonizing the Critique.

Omics : a journal of integrative biology·2025
Same author

The Art of Critique.

Omics : a journal of integrative biology·2025
Same author

United Nations, the Struggle for Gender Equity, and Queering Global Science.

Omics : a journal of integrative biology·2025
Same author

Artificial Intelligence and Environmental Impact: Moving Beyond Humanizing Vocabulary and Anthropocentrism.

Omics : a journal of integrative biology·2024

Area of Science:

  • Neuropharmacology
  • Psychiatry
  • Drug Development

Background:

  • Aripiprazole is being developed for psychoses, including schizophrenia.
  • Its unique mechanism involves dopamine D2 receptor modulation.
  • Schizophrenia treatment faces challenges with existing antipsychotics.

Purpose of the Study:

  • To evaluate aripiprazole's efficacy and safety in treating psychoses.
  • To understand its novel dual-acting dopamine receptor mechanism.
  • To assess its potential as an atypical antipsychotic.

Main Methods:

  • Neuropharmacological studies in animal models.
  • Clinical trials (Phase III) for schizophrenia.
  • Analysis of D2 receptor and c-fos mRNA expression.

Related Experiment Videos

Main Results:

  • Aripiprazole acts as a presynaptic D2 agonist and postsynaptic D2 antagonist.
  • It inhibits apomorphine-induced stereotypy without catalepsy in animals.
  • Low risk of extrapyramidal side effects observed, with no D2 receptor upregulation.

Conclusions:

  • Aripiprazole represents a significant atypical antipsychotic candidate.
  • Its distinct mechanism offers potential advantages over traditional antipsychotics.
  • Favorable safety profile suggests therapeutic potential for schizophrenia and other psychotic disorders.